FDA declines approval for Sunovion’s ADHD drug dasotraline, citing need for more data
In a regulatory setback, the U.S. Food and Drug Administration (FDA) has decided not to approve Sunovion Pharmaceuticals’ dasotraline, a dual-acting dopamine and norepinephrine reuptake ... Read More
FDA sets review date for Ironshore Pharmaceuticals’ ADHD drug HLD200
Ironshore Pharmaceuticals & Development, a subsidiary of Highland Therapeutics, has reached a significant milestone with the U.S. Food and Drug Administration’s (FDA) acceptance of their ... Read More